Brand Name

Filspari

Generic Name
Sparsentan
View Brand Information
FDA approval date: February 17, 2023
Classification: Endothelin Receptor Antagonist
Form: Tablet

What is Filspari (Sparsentan)?

FILSPARI is indicated to slow kidney function decline in adults with primary immunoglobulin A nephropathy who are at risk for disease progression. FILSPARI is an endothelin and angiotensin II receptor antagonist indicated to slow kidney function decline in adults with primary immunoglobulin A nephropathy who are at risk for disease progression ( 1, 1.

Approved To Treat

Top Global Experts

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

A Multi-centre, Open-label, Exploratory Trial of the Safety and Activity of Sparsentan for the Treatment of Incident (Cohort A) and Recurrent (Cohort B) Patients With Immunoglobulin A Nephropathy
A Multi-centre, Open-label, Exploratory Trial of the Safety and Activity of Sparsentan for the Treatment of Incident (Cohort A) and Recurrent (Cohort B) Patients With Immunoglobulin A Nephropathy
Who is this study for: Patients newly-diagnosed with immunoglobulin A nephropathy
Enrollment Status: Recruiting
Publish Date: June 03, 2026
Intervention Type: Drug
Study Drug: Sparsentan
Study Phase: Phase 2

Summary: To determine the nephroprotective potential of treatment with sparsentan in (1: Cohort A) patients newly-diagnosed with immunoglobulin A nephropathy (IgAN) (ie, incident patients) who have not received prior angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) therapy, and in (2: Cohort B) patients with recurrent IgAN following kidney transplantation.

A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Treatment in Pediatric Subjects With Selected Proteinuric Glomerular Diseases
A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Treatment in Pediatric Subjects With Selected Proteinuric Glomerular Diseases
Enrollment Status: Recruiting
Publish Date: May 12, 2026
Intervention Type: Drug
Study Phase: Phase 2

Summary: To evaluate the safety, efficacy and tolerability of sparsentan oral suspension and tablets, and assess changes in proteinuria after once-daily dosing over 108 weeks.

A Multicenter, Open-label Single Arm Study to Evaluate the Safety and Efficacy of Sparsentan in Posttransplant Immunoglobulin A Nephropathy (IgAN) or Focal Segmental Glomerulosclerosis (FSGS) (SPARX)
A Multicenter, Open-label Single Arm Study to Evaluate the Safety and Efficacy of Sparsentan in Posttransplant Immunoglobulin A Nephropathy (IgAN) or Focal Segmental Glomerulosclerosis (FSGS) (SPARX)
Enrollment Status: Recruiting
Publish Date: February 27, 2026
Intervention Type: Drug
Study Phase: Phase 4

Summary: To evaluate the safety and efficacy of sparsentan tablets for the treatment of patients with proteinuria after kidney transplantation with once-daily dosing for 36 weeks.

View All Clinical Trials

Related Latest Advances

New and Emerging Nonimmunosuppressive Drug Therapies for Primary Adult Glomerular Diseases.
New and Emerging Nonimmunosuppressive Drug Therapies for Primary Adult Glomerular Diseases.
Journal: Kidney medicine
Published: May 21, 2026
Review of the clinical, humanistic, and economic burden of focal segmental glomerulosclerosis.
Review of the clinical, humanistic, and economic burden of focal segmental glomerulosclerosis.
Journal: The American journal of managed care
Published: May 08, 2026
Sparsentan for the Treatment of Immunoglobulin A Nephropathy: An Innovative Concept for Economic Modelling.
Sparsentan for the Treatment of Immunoglobulin A Nephropathy: An Innovative Concept for Economic Modelling.
Journal: Journal of clinical medicine
Published: April 17, 2026
View All Latest Advances